Michael A. Goldstein
Papers
1
Total Citations
232
H-Index
1
About
Michael A. Goldstein is a leading figure in radiation oncology, with a primary focus on the treatment of gastrointestinal malignancies, particularly pancreatic cancer. His most influential work, the 2010 study "Stereotactic Body Radiotherapy and Gemcitabine for Locally Advanced Pancreatic Cancer," has garnered over 230 citations, establishing a foundational approach for combining high-dose, precisely targeted radiation with systemic chemotherapy. This research demonstrated the feasibility and efficacy of stereotactic body radiotherapy (SBRT) in a disease traditionally considered radioresistant, offering a new paradigm for local control in a challenging clinical setting. Beyond this landmark paper, Goldstein’s contributions extend to optimizing radiation delivery techniques and integrating novel systemic agents to improve outcomes for patients with locally advanced and metastatic disease. His work has been instrumental in shifting clinical practice toward more aggressive, yet tolerable, non-surgical interventions. Through rigorous clinical trials and translational research, Goldstein continues to shape the standard of care, making him a pivotal voice in the ongoing effort to improve survival and quality of life for pancreatic cancer patients.
Research Focus
Key Achievements
Top Papers
- 1